IPP Bureau
Dr Reddy’s enters hormone replacement therapy market with landmark brand acquisition
By IPP Bureau - February 19, 2026
The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
Merck, Mayo Clinic forge AI powerhouse to accelerate drug discovery
By IPP Bureau - February 19, 2026
Lilly breakthrough: Dual treatment clears skin & cuts weight in psoriasis patients
By IPP Bureau - February 19, 2026
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg
By IPP Bureau - February 19, 2026
Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension
GSK announces breakthrough data showing RSV vaccine cuts hospitalizations in elderly
By IPP Bureau - February 19, 2026
The data highlights its RSV vaccine cuts hospitalizations in older adults
GSK’s Exdensur wins EU nod for severe asthma
By IPP Bureau - February 19, 2026
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
Evinova teams up with Astellas, AstraZeneca & Bristol Myers Squibb to supercharge clinical trials with AI
By IPP Bureau - February 19, 2026
Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care
Catalent and S.Biomedics join forces to advance groundbreaking Parkinson’s therapy
By IPP Bureau - February 19, 2026
TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform
European Commission greenlights higher-dose Wegovy for obese adults
By IPP Bureau - February 18, 2026
Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose
Pfizer’s BRAFTOVI regimen shows major breakthrough in aggressive colorectal cancer
By IPP Bureau - February 18, 2026
BREAKWATER is a Phase 3, randomized, open-label trial testing BRAFTOVI in combination with cetuximab, either alone or with chemotherapy, in patients with untreated BRAF V600E-mutant mCRC
ExCellThera’s Zemcelpro scores big in Germany, paving way for early hospital access
By IPP Bureau - February 18, 2026
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
LEX Diagnostics gets FDA nod and CLIA waiver for ultra-fast VELO system
By IPP Bureau - February 18, 2026
The VELO system supports multiplex testing for Influenza A, Influenza B, and COVID-19, producing PCR results in six to ten minutes
Evogene and QUT join forces to tackle chemotherapy-resistant lung cancer with AI
By IPP Bureau - February 18, 2026
Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC
Scinai acquires Recipharm Israel to expand global reach
By IPP Bureau - February 18, 2026
This transaction fundamentally strengthens Scinai's CDMO platform
